sulpiride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sulpiride derivatives	2537	15676-16-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sulpiride sulpirid sulpitil sulpyrid sursumid	A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed) Molecular weight: 341.43 Formula: C15H23N3O4S CLOGP: 1.11 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 101.73 ALOGS: -2.80 ROTB: 6

Drug dosage:

Dose	Unit	Route
0.80	g	O
0.80	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.28 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	133.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	27 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.94 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1972	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Torsade de pointes	152.36	105.06	26	195	2220	2355644
Electrocardiogram QT prolonged	137.23	105.06	29	192	7785	2350079
Parkinsonism	126.72	105.06	21	200	1484	2356380
Ventricular fibrillation	125.48	105.06	22	199	2179	2355685

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	125.79	49.60	24	142	3124	1743491
Parkinsonism	70.52	49.60	13	153	1356	1745259
Poisoning deliberate	56.39	49.60	10	156	832	1745783
Abdominal pain upper	52.49	49.60	15	151	10986	1735629

Pharmacologic Action:

Source	Code	Description
ATC	N05AL01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Benzamides
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018687	Antidepressive Agents, Second-Generation
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:50919	antiemetic
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:48561	dopaminergic antagonist
MeSH PA	D014149	Tranquilizing Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Schizophrenia	indication	58214004	DOID:5419

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	acidic
pKa2	12.66	acidic
pKa3	8.85	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.12		CHEMBL	IUPHAR
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	7.40		WOMBAT-PK
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.76		CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	8.41		CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.68		CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	8.10		CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	4.97		CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.44		CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	7.51		CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	5.92		CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	7.74		CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	9.10		CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.12		DRUG MATRIX
Dopamine receptor	GPCR		DRD1_RAT DRD2_RAT DRD3_RAT DRD4_RAT DRD5_RAT		Ki	5.80		CHEMBL
Alpha carbonic anhydrase	Unclassified		B5SU02_9CNID		Ki	6.37		CHEMBL
Astrosclerin-3	Unclassified		A6YCJ1_9METZ		Ki	6.42		CHEMBL
Beta-carbonic anhydrase 1	Enzyme		MTCA1_MYCTU		Ki	5.64		CHEMBL
Carbonic anhydrase	Unclassified		C0IX24_9CNID		Ki	6.38		CHEMBL
Delta carbonic anhydrase	Unclassified		Q5U9J1_THAWE		Ki	6.59		CHEMBL
Carbonic anhydrase	Enzyme		CAN_YEAST		Ki	6.91		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_CANFA		IC50	6.70		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Kd	8.82		CHEMBL
Carbonic anhydrase	Enzyme		CYNT_HELPY		Ki	6.75		CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	7.14		CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	7.40		CHEMBL
Carbonic anhydrase 2	Enzyme		MTCA2_MYCTU		Ki	6.58		CHEMBL
Carbonic anhydrase	Unclassified		Q5TU56_ANOGA		Ki	7.53		CHEMBL
Carbonic anhydrase	Enzyme		Q6FTL6_CANGA		Ki	6.95		CHEMBL

External reference:

ID	Source
N0000166882	NUI
C0038803	UMLSCUI
D01226	KEGG_DRUG
7MNE9M8287	UNII
2359	INN_ID
321506004	SNOMEDCT_US
10239	RXNORM
395891007	SNOMEDCT_US
003764	NDDF
CHEMBL26	ChEMBL_ID
DB00391	DRUGBANK_ID
CHEBI:32168	CHEBI
D013469	MESH_DESCRIPTOR_UI
5355	PUBCHEM_CID
5501	IUPHAR_LIGAND_ID

Pharmaceutical products:

None